-
1.发明公开公开(公告)号：US20230181590A1
公开(公告)日：2023-06-15
申请号：US18063190
申请日：2022-12-08
发明人： Christian HESSLINGER , Verena BAUER , Sebastian Martin BOSSERT , Susan KOBER , Yi LIU , Peter NICKOLAUS , Maria SARNO , Florian VOSS
IPC分类号： A61K31/519 , A61K9/28 , A61K9/00 , A61P11/00
CPC分类号： A61K31/519 , A61K9/28 , A61K9/0053 , A61P11/00
摘要： The invention concerns an oral pharmaceutical composition consisting essentially of
the PDE4B-inhibitor of formula III
in the dose of 18 mg or 9 mg and
optionally of one or more pharmaceutically acceptable carriers or excipients
for use in the treatment of a patient suffering from one or more progressive fibrosing interstitial lung diseases (PF-ILD), wherein this oral pharmaceutical composition is to be administered to the patient twice daily.
The invention further concerns oral pharmaceutical compositions comprising the PDE4B-inhibitor of formula III in the dose of 18 mg or 9 mg and a therapeutically effective dose of a second active ingredient selected from nintedanib or pirfenidone, wherein these oral pharmaceutical compositions are administered to the patient twice daily.-
2.发明公开公开(公告)号：US20230190754A1
公开(公告)日：2023-06-22
申请号：US18063196
申请日：2022-12-08
发明人： Christian HESSLINGER , Verena BAUER , Sebastian Martin BOSSERT , Susan KOBER , Yi LIU , Peter NICKOLAUS , Maria SARNO , Florian VOSS
IPC分类号： A61K31/519 , A61K31/4418 , A61K31/496 , A61P11/00
CPC分类号： A61K31/519 , A61K31/4418 , A61K31/496 , A61P11/00 , A61K9/0053
摘要： The invention concerns an oral pharmaceutical composition comprising
either 18 mg or 9 mg of the PDE4B-inhibitor of formula III
a therapeutically effective dose of a second active agent selected from the group consisting of nintedanib or pirfenidone and
optionally, one or more pharmaceutically acceptable carriers or excipients for the treatment of a patient suffering from a progressive fibrosing interstitial lung disease (PF-ILD), wherein this oral pharmaceutical composition is to be administered to said patient twice daily.
The invention further concerns the use of the PDE4B-inhibitor of formula III for preparing an oral pharmaceutical composition comprising either 18 mg or 9 mg of the PDE4B-inhibitor of formula III for use in a method of treating a patient suffering from one or more Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs), wherein said oral pharmaceutical composition is to be orally administered twice daily to said patient in combination with a therapeutically effective amount of a therapeutically effective dose of a second active agent selected from the group consisting of nintdanib and pirfenidone.
-
搜索结果
2 条记录 (耗时 0.011 秒)
